Advertisement

Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy

      Highlights

      • Chemotherapy Response Score is prognostic.
      • Lymphocytic infiltration in pretreatment biopsies is prognostic.
      • Bevacizumab administration may adversely affect the survival of patients with lymphocytic infiltration.

      Abstract

      Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an accepted frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT may provide a surrogate for response to treatment. The present study aims to characterize the pathological response and to examine its prognostic significance in these patients. Medical records of women with EOC treated in our institution from 2011 to 2016 were retrospectively identified. IDS specimens were reviewed by study pathologist and Chemotherapy Response Score (CRS), lymphocytic infiltration, necrosis and mitosis were assessed. 55 patients with EOC treated with NACT were identified and 48 had complete clinical and pathological data. Median age was 63 years. CRS assessed at omentum predicted PFS when adjusted for age, stage, debulking status (complete, optimal, suboptimal) and post IDS bevacizumab administration (mPFS CRS 1 vs 2 vs 3: 10.3–14–18.7 months 95% CI [7.4–15.7], [12.2–22.9], [13.5–31.3]). Presence of lymphocytic infiltration was associated with improved OS (log-rank test P = 0.015). Post IDS bevacizumab was associated with shorter PFS in patients with lymphocytic infiltration. BRCA status was known for 25 patients and presence of BRCA1/2 mutations was strongly correlated with lymphocytic infiltration (P = 0.011) but not CRS omentum (P = 0.926). Our study confirms the predictive value of CRS in EOC patients treated with NACT and IDS, but also demonstrates the prognostic significance of lymphocytic infiltration as well as its possible interaction with bevacizumab treatment.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Burger R.A.
        • et al.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2473-2483
        • Perren T.J.
        • et al.
        A phase 3 trial of bevacizumab in ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2484-2496
        • Vergote I.
        • et al.
        Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
        N. Engl. J. Med. 2010; 363: 943-953
        • Fagotti A.
        • et al.
        Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome.
        Eur. J. Cancer. 2016; 59: 22-33
        • Kehoe S.
        • et al.
        Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
        Lancet. 2015; 386: 249-257
        • Bohm S.
        • et al.
        Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
        J. Clin. Oncol. 2015; 33: 2457-2463
        • McCluggage W.G.
        • et al.
        Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).
        Mod. Pathol. 2015; 28: 1101-1122
        • Ditzel H.M.
        • et al.
        Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC).
        Int. J. Gynecol. Pathol. 2019; 38: 230-240
        • Lee J.Y.
        • et al.
        External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
        J. Gynecol. Oncol. 2017; 28e73
        • Coghlan E.
        • et al.
        Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma.
        International Journal of Gynecologic Cancer. 2017; 27: 708-713
        • Rajkumar S.
        • et al.
        Prognostic implications of histological tumor regression (Böhm’s score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
        Gynecol. Oncol. 2018; 151: 264-268
        • Singh P.
        • et al.
        The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
        Histopathology. 2018; 72: 619-625
        • Salgado R.
        • et al.
        The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
        Ann. Oncol. 2015; 26: 259-271
        • James F.R.
        • et al.
        Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.
        BMC Cancer. 2017; 17: 657-663
        • Collett D.
        Modelling Survival Data in Medical Research.
        3rd ed. Chapman and Hall/CRC, New York2014
        • Klein J.
        • Moeschberger M.
        Survival Analysis: Techniques for Censored and Truncated Data.
        2nd ed. Springer-Verlag, New York2003
        • Cox D.R.
        Regression models and life-tables.
        J. R. Stat. Soc. Ser. B (Method.). 1972; 34: 187-220
        • Hess K.R.
        Graphical methods for assessing violations of the proportional hazards assumption in cox regression.
        Stat. Med. 1995; 14: 1707-1723
        • Grambsch P.M.
        • Therneau T.M.
        Proportional hazards tests and diagnostics based on weighted residuals.
        Biometrika. 1994; 81: 515-526
        • Böhm S.
        • et al.
        Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
        J. Clin. Oncol. 2015; 33: 2457-2463
        • Bohm S.
        • et al.
        Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.
        Int. J. Gynecol. Cancer. 2019; 29: 353-356
        • Cohen P.A.
        • et al.
        Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data.
        Gynecol. Oncol. 2019; 154: 441-448
        • Coghlan E.
        • et al.
        Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma.
        Int. J. Gynecol. Cancer. 2017; 27: 708-713
        • Vermeulen C.K.M.
        • et al.
        Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
        European Journal of Obstetrics and Gynecology and Reproductive Biology. 2017; 219: 100-105
        • Zhang L.
        • et al.
        Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
        N. Engl. J. Med. 2003; 348: 203-213
        • Hamanishi J.
        • et al.
        Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
        Proc. Natl. Acad. Sci. 2007; 104: 3360-3365
        • Li J.
        • et al.
        The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
        Oncotarget. 2017; 8: 15621-15631
        • Sato E.
        • et al.
        Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
        Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 18538-18543
        • Gourley C.
        • et al.
        Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.
        Journal of Clinical Oncology. 2014; 32: 5502
        • Hamanishi J.
        • et al.
        Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.
        J. Clin. Oncol. 2015; 33: 4015-4022
        • Matulonis U.A.
        • et al.
        Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
        Ann. Oncol. 2019; 30: 1080-1087
        • Rahma O.E.
        • Hodi F.S.
        The intersection between tumor angiogenesis and immune suppression.
        Clin. Cancer Res. 2019; 25: 5449-5457
        • Choueiri T.K.
        • et al.
        Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
        Journal of Clinical Oncology. 2019; 37: 101
        • Ueda S.
        • et al.
        Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis.
        Clin. Cancer Res. 2017; 23: 5769-5778
        • Gavalas N.G.
        • et al.
        VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2.
        Br. J. Cancer. 2012; 107: 1869-1875
        • Tsiatas M.L.
        • et al.
        Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
        International Journal of Gynecologic Cancer. 2009; 19 (-1334-1329-1334): 1329
        • Ray-Coquard I.
        • et al.
        Olaparib plus bevacizumab as first-line maintenance in ovarian cancer.
        N. Engl. J. Med. 2019; 381: 2416-2428
        • Moore K.
        • et al.
        Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2018; 379: 2495-2505
        • González-Martín A.
        • et al.
        Niraparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2019; 381: 2391-2402